TREATMENT OF EXPERIMENTAL NEPHROSIS BY CULTURE FILTRATE OF CRYPTOCOCCUS NEOFORMANS VAR. GATTII (CneF)

REFERENCES

• Levitz S.M. The Ecology of Cryptococcus Neoformans and the Epidemiology of Cryptococcosis. Rev. Infect. Dis. 1991; 13: 1163–1169
   PubMedGoogle Scholar
• Patterson T.F., Andriole V.T. Current Concepts in Cryptococcosis. Eur. J. Clin. Microbiol. Infect. Dis. 1989; 8: 457–465
   PubMed Web of Science ®Google Scholar
• Khardori N. Host-Parasite Interaction in Fungal Infections. Eur. J. Clin. Microbiol. Infect. Dis. 1989; 8: 331–351
   PubMedGoogle Scholar
• Ellis D.H., Pfeiffer T.F. Natural Habitat of Cryptococcus Neoformans var. gattii. J. Clin. Microbiol. 1990; 28: 1642–1644
   PubMed Web of Science ®Google Scholar
• Dong Z.M., Murphy J.W. Effects of the Two Varieties of Cryptococcus Neoformans Cells and Culture Filtrate Antigens on Neutrophil Locomotion. Infect. Immun. 1995; 63: 2632–2644
   PubMed Web of Science ®Google Scholar
• Kwon-Chung K.J., Bennett J.E. Epidemiologic Differences Between the Two Varieties of Cryptococcus Neoformans. Am. J. Epidemiol. 1984; 120: 123–130
   PubMed Web of Science ®Google Scholar
• Eng R., Bishburg E., Smith S.M., Kapila R. Cryptococcal Infections in Patients with Acquired Immune Deficiency Syndrome. Am. J. Med. 1986; 81: 19–23
   PubMed Web of Science ®Google Scholar
• Kwon-Chung K.J., Bennett J.E. Cryptococcosis. medical mycology. Lea and Febiger, Malvern, Pa 1992; 397–446
   Google Scholar
• Sugar A.M. Overview: Cryptococcosis in Patients with AIDS. Mycopathologia. 1991; 114: 153–157
   PubMedGoogle Scholar
• Cherniak R., Sundstrom J.B. Polysaccharide Antigens of the Capsule of Cryptococcus Neoformans. Infect. Immun. 1994; 62: 1507–1512
   PubMed Web of Science ®Google Scholar
• Orendi J.M., Verheul A.F.M., Devos N.M., Visser M.R., Snippe H., Cherniak R., Vaishnav V.V., Rijkers G.T., Verhoef J. Mannoproteins of Cryptococcus Neoformans Induce Proliferative Response in Human Peripheral Blood Mononuclear Cells (PBMC) and Enhance HIV-1 Replication. Clin. Exp. Immunol. 1997; 107: 293–299
   PubMed Web of Science ®Google Scholar
• Cherniak R., Reiss E., Slodki M.E., Plattner R.D., Blummer S.O. Structure and Antigenic Activity of the Capsular Polysaccharide from Cryptococcus Neoformans Serotype A. Mol. Immunol. 1980; 17: 1025–1032
   PubMed Web of Science ®Google Scholar
• Cherniak R., Morris L.C., Anderson B.C., Meyer S.A. Facilitated Isolation, Purification, and Analysis of Glucuronoxylomannan of Cryptococcus Neoformans. Infect. Immun. 1991; 59: 59–64
   PubMed Web of Science ®Google Scholar
• Chaka W., Verheul A.F.M., Vaishnav V.V., Cherniak R., Scharringa J., Verhoef J., Snippe H., Hoepelman I.M. Cryptococcus Neoformans and Cryptococcal Glucuronoxylomannan, Galactoxylomannan, and Mannoprotein Induce Different Levels of Tumor Necrosis Factor Alpha in Human Peripheral Blood Mononuclear Cells. Infec. Immun. 1997; 65: 272–278
   PubMedGoogle Scholar
• Dong Z.M., Murphy J.W. Intravascular Cryptococcal Culture Filtrate (CneF) and its Major Component, Glucuronoxylomannan, are Potent Inhibitors of Leukocyte Accumulation. Infect. Immun. 1995; 63: 770–778
   PubMed Web of Science ®Google Scholar
• Dong Z.M., Murphy J.W. Cryptococcal Polysaccharides Bind to CD18 on Human Neutrophils. Infect. Immun. 1997; 65: 557–563
   PubMed Web of Science ®Google Scholar
• Breen J.F., Lee I.C., Vogel F.R., Friedman H. Cryptococcal Capsular Polysaccharide-induced Modulation of Murine Immune Responses. Infect. Immun. 1982; 36: 47–51
   PubMed Web of Science ®Google Scholar
• Kozel T.R., Gotschlich E. The Capsule of Cryptococcus Neoformans Passively Inhibits Phagocytosis of the Yeast by Macrophages. J. Immunol. 1982; 129: 1675–1680
   PubMed Web of Science ®Google Scholar
• Drouhet E., Segretain G. Inhibition de la Migration Leucocytaire in vitro par un Polyoside Capsulaire de Torulopsis (Cryptococcus) Neoformans. Ann. Inst. Pasteur. 1951; 81: 674
   PubMedGoogle Scholar
• Dong Z.M., Jackson L., Murphy J.W. Mechanisms for Induction of L-selectin Loss from T Lymphocytes by a Cryptococcal Polysaccharide, Glucuronoxylomannan. Infect. Immun. 1999; 67: 220–229
   PubMedGoogle Scholar
• Dong Z.M., Murphy J.W. Cryptococcal Polysaccharides Induce L-Selectin Shedding and Tumor Necrosis Factor Receptor Loss from the Surface of Human Neutrophils. J. Clin. Invest. 1996; 97: 689–698
   PubMed Web of Science ®Google Scholar
• Retini C., Vecchiarelli A., Monari C., Bistoni F., Kozel T.R. Encapsulation of Cryptococcus Neoformans with Glucuronoxylomannan Inhibits the Antigen-presenting Capacity of Monocytes. Infect. Immun. 1998; 66: 664–669
   PubMedGoogle Scholar
• de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin-10 (IL-10) inhibits Cytokine Synthesis by Human Monocyte: An Autoregulatory Role of IL-10 Produced by Monocytes. J. Exp. Med. 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• Levitz S.M., Tabuni A., Nang S.H., Golenbock D.T. Effects of Interleukin-10 on Human Peripheral Blood Mononuclear Cell Responses to Cryptococcus Neoformans, Candida albicans, and Lipopolysaccharide. Infect. Immun. 1996; 64: 945–951
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A., Retini C., Monari C., Tascini C., Bistoni F., Kozel T.R. Purified Capsular Polysaccharide of Cryptococcus Neoformans Induces Interleukin-10 Secretion by Human Monocytes. Infect. Immun. 1996; 64: 2846–2849
   PubMedGoogle Scholar
• Lipovsky M.M., Gekker G., Hu S., Ehrlich L.C., Hoepelman A.I.M., Peterson P.K. Cryptococcal Glucuronoxylomannan Induces Interleukin (IL)-8 Production by Human Microglia but Inhibits Neutrophil Migration Toward IL-8. J. I. D. 1998; 177: 260–263
   PubMed Web of Science ®Google Scholar
• Washburn R.G., Bryant-Varela B.J., Julian N.C., Bennett J. Differences in Cryptococcus Neoformans Capsular Polysaccharide Structure Influence Assembly of Alternative Complement Pathway C3 Convertase Fungal Surfaces. Mol. Immunol. 1991; 28: 465–470
   PubMedGoogle Scholar
• Young B.J., Kozel T.R. Effects of Strain Variation, Serotype, and Structural Modification on Kinetics for Activation and Binding of C3 to Cryptococcus Neoformans. Infect. Immun. 1993; 61: 2966–2972
   PubMedGoogle Scholar
• Buchanan K.L., Murphy J.W. Characterization of Cellular Infiltrations and Cytokine Production during the Expression Phase of the Anticryptococcal Delayed-type Hypersensitivity Response. Infect. Immun. 1993; 61: 2854–2865
   PubMed Web of Science ®Google Scholar
• Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein Measurement with the Folin Phenol Reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric Method for Determination of Sugars and Related Substances. Anal. Chem. 1956; 28: 350–356
   Web of Science ®Google Scholar
• Bousnes R.W., Taussky A.A. The Calorimetric Determination of Creatinine by the Jaffe Reaction. J. Biol. Chem. 1945; 158: 581–591
   Web of Science ®Google Scholar
• Veniamin M.P., Vakirtzi-Lemonias C. Chemical Basis of the Carbamidodiacetyl Micromethod for Estimation of Urea, Citrulline and Carbamyl Derivatives. Clin. Chem. 1970; 16: 3–6
   PubMedGoogle Scholar
• Bustos C., González-Cuadrado S., Ruiz-Ortega M., Goméz-Guerrero C., González E., Plaza J.J., Edigo J. Cyclosporin A (CsA) Modulates the Glomerular Production of Inflammatory Mediators and Proteoglycans in Experimental Nephrosis. Clin. Exp. Immunol. 1995; 102: 608–613
   PubMedGoogle Scholar
• Ortíz A., Egido J. Is there a Role for Specific Anti-TNF Strategies in Glomerular Diseases?. Nephrol. Dial. Transplant. 1995; 10: 309–311
   PubMed Web of Science ®Google Scholar
• Gómez-Chiarri M., Ortíz A., Lerma J.L., Mampaso F., González E., Egido E. Involvement of Tumor Necrosis Factor and Platelet Activating Factor in the Pathogenesis of Experimental Nephrosis in Rats. Lab. Invest. 1994; 70: 449–459
   PubMedGoogle Scholar
• Hruby Z.W., Jothy S., Lowry R.P. Antiserum Against Tumor Necrosis Factor-alpha and a Protease Inhibitor Reduce Immune Glomerular Injury. Kidney. Int. 1991; 40: 43–51
   PubMedGoogle Scholar
• Perico N., Delaini F., Taglia Ferri M., Abbate M., Cucchi M., Bertani T., Remuzzi G. Effect of Platelet-activating Factor and its Specific Receptor Antagonist on Glomerular Permeability to Proteins in Isolated Perfused Rat Kidney. Lab. Invest. 1988; 58: 163–171
   PubMedGoogle Scholar
• Bertani T., Abbate M., Zoja C., Corna D., Perico N., Ghezzi P., Remuzzi G. Tumor Necrosis Factor Induces Glomerular Damage in the Rabbit. Am. J. Pathol. 1989; 134: 419–430
   PubMed Web of Science ®Google Scholar
• Gómez-Chiarri M., Egido J., Emancipator S., Hamilton T.A. Interferon Gamma (IFN) and Bacterial Endotoxin (LPS) Induce IP-10 Early Gene Expression in Murine Mesangial Cells. Am. J. Pathol. 1993; 142: 433–439
   PubMedGoogle Scholar
• Ortíz A., Alonso J., Gómez-Chiarri M., Lerma J.L., Seron D., Condom E., González E., Egido J. Fibronectin (FN) Decreases Glomerular Lesions and Synthesis of Tumour Necrosis Factor-alpha (TNF-α), Platelet-activating Factor (PAF) and FN in Proliferative Glomerulonephritis. Clin. Exp. Immunol. 1995; 101: 334–340
   PubMedGoogle Scholar
• Fujihara H., Kagaya K., Fukazawa Y. Anti-chemotactic Activity of Capsular Polysaccharide of Cryptococcus Neoformans in vitro. Microbiol. Immunol. 1997; 41: 657–664
   PubMedGoogle Scholar
• Vecchiarelli A., Monari C., Retini C., Pietrella D., Palazzetti B., Pitzurra L., Casadevall A. Cryptococcus Neoformans Differently Regulates B7-1 (CD80) and B7-2 (CD86) Expression on Human Monocytes. Eur. J. Immunol. 1998; 28: 114–121
   PubMedGoogle Scholar
• Murphy J.W., Zhou A., Wong S.C. Direct Interactions of Human Natural Killer Cells with Cryptococcus Neoformans Inhibit Granulocyte-macrophage Colony-stimulating Factor and Tumor Necrosis Factor Alpha Production. Infect. Immun. 1997; 65: 4564–4571
   PubMedGoogle Scholar
• Mozaffarian N., Casadevall A., Berman J.W. Inhibition of Human Endothelial Cell Chemokine Production by the Opportunistic Fungal Pathogen Cryptococcus Neoformans. J. Immunol. 2000; 165: 1541–1547
   PubMedGoogle Scholar
• Desassis J.F., Raats C.J.I., Bakker M.A.H., van den Born J., Berden J.H.M. Antiproteinuric Effect of Cyclosporin A in Adriamycin Nephropathy in Rats. Nephron. 1997; 75: 336–341
   PubMed Web of Science ®Google Scholar
• Fujita M., Iida H., Asaka M., Izumino K., Takata M., Sasayama S. Effect of the Immunosuppressive Agent, Cyclosporin, on Experimental Immune Complex Glomerulonephritis in Rats. Nephron. 1991; 57: 201–205
   PubMed Web of Science ®Google Scholar
• Vaziri N.D., Liang K.H. Down-regulation of Hepatic LDL Receptor Expression in Experimental Nephrosis. Kidney. Int. 1996; 50: 887–893
   PubMedGoogle Scholar
• Harris D.C., Tay Y.C. Mitochondrial Function in Rat Renal Cortex in Response to Proteinuria and Iron. Clin. Exp. Pharmacol. Physiol. 1997; 24: 916–922
   PubMedGoogle Scholar
• Eng R., Chmel H., Corrado M., Smith S.M. The Course of Cryptococcal Capsular Polysaccharide Antigenemia/human Cryptococcal Polysaccharide Elimination Kinetics. Infection. 1983; 11: 132–136
   PubMed Web of Science ®Google Scholar